Early Administration of Heparin At FMC for PPCI of STEMI Patients

Summary

Heparin is the first choice of anticoagulation drug for primary PCI of STEMI patients. However, the priority of use of hepairn in first medical contact or in Cathlab has not yet studied. Previous study revealed early use of antithrombotic drugs could improve patient's survival. Here we supposed that use of heparin at first medical contact could increase the TIMI flow 3 grade ratio in STEMI patients and improve patient's survival and/or reduce MACE rather than in Cathlab.

Conditions

• STEMI
• Primary PCI

Interventions

DRUG

Heparin Sodium Injection

Heparin Sodium Injection (100U/Kg body weight)

Sponsors & Collaborators

• Xiangyang Central Hospital

  collaborator OTHER

• The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture

  collaborator OTHER

• Wuhan Central Hospital

  collaborator OTHER

• People's Hospital of Jingshan

  collaborator UNKNOWN

• Chibi General Hospital

  collaborator UNKNOWN

• Xianning Central Hospital

  collaborator OTHER

• Hubei University of Medicine

  collaborator OTHER

• Yichang Central People's Hospital

  collaborator OTHER

• People's Hospital of Tongcheng

  collaborator UNKNOWN

• Ezhou Central Hospital

  collaborator UNKNOWN

• Xiantao First People's Hospital

  collaborator UNKNOWN

• Songzi People's Hospital

  collaborator UNKNOWN

• Anlu People's Hospital

  collaborator UNKNOWN

• Caidian People's Hospital

  collaborator UNKNOWN

• Jiangxia First People's Hospital

  collaborator UNKNOWN

• Jingzhou Central Hospital

  collaborator OTHER

• Hubei Zhongshan Hospital

  collaborator UNKNOWN

• Guoyao Dongfeng General Hospital

  collaborator UNKNOWN

• Wuhan Puren Hospital

  collaborator OTHER

• Shiyan People's Hospital

  collaborator UNKNOWN

• General Hospital of Yangtze River shipping

  collaborator UNKNOWN

• Fifth Hospital in Wuhan

  collaborator UNKNOWN

• CR & WISCO General Hospital

  collaborator UNKNOWN

• Xishui People's Hospital

  collaborator UNKNOWN

• Jiangling People's Hospital

  collaborator UNKNOWN

• Wuhan Third Hospital

  collaborator OTHER

• Laohekou First Hospital

  collaborator UNKNOWN

• The Central Hospital of Huanggang

  collaborator OTHER

• Wuhan No.1 Hospital

  collaborator OTHER

• Hanyang University

  collaborator OTHER

• Wuxue First People's Hospital

  collaborator UNKNOWN

• Tianmen First People's Hospital

  collaborator UNKNOWN

• Xianning First People's Hospital

  collaborator UNKNOWN

• Wuhan No.6 Hospital

  collaborator UNKNOWN

• Wuhan Hospital of Traditional Chinese Medicine

  collaborator OTHER

• Renmin Hospital of Wuhan University

  lead OTHER

Principal Investigators

• Jing Chen, PhD · Renmin Hospital of Wuhan University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-07-20

Primary Completion

2023-08-20

Completion

2024-08-20

Countries

• China

Study Locations